Figure 2From: Clinical feasibility of (neo)adjuvant taxane-based chemotherapy in older patients: analysis of >4,500 patients from four German randomized breast cancer trialsDose reduction, dose delay, hospitalization, therapy discontinuation, and death per patient, versus age group.Back to article page